Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

EarningsFanapt®BYSANTI™Positive

AI Analysis

Summary

Vanda Pharmaceuticals reported Q2 2026 results with Fanapt net product sales increasing 23% to $36.0 million and total prescriptions up 31%, while raising full-year revenue guidance to $240-$290 million. The company maintains $170.0 million in cash, sufficient to fund operations through at least the end of 2027.

Financial Highlights

Revenue

$36.0 million (Fanapt Q2 2026)

Guidance

$240-$290 million (full-year 2026 total revenue)

Importance:3/10

Sentiment:

0.60

earningsproduct sales growthrevenue guidancecash position

Related Companies

$VNDA

Read the original article

Published by PR Newswire Pharma on August 5, 2026 8:01 PM

Read Original